Burning Rock Biotech Ltd. (BNR)
NASDAQ:BNR
Want to see BNR full AI Analyst Report?
BNR Stock Chart & Stats
$23.40
<$0.01(0.06%)
At close: 4:00 PM EST
$23.40
<$0.01(0.06%)
Day’s Range― - ―
52-Week Range$2.49 - $41.72
Previous CloseN/A
Volume1.44K
Average Volume (3M)22.64K
Market Cap
$179.23M
Enterprise Value-$314.91M
Total Cash (Recent Filing)$481.39M
Total Debt (Recent Filing)$43.15M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-51.80
Shares Outstanding8,813,858
10 Day Avg. Volume13,298
30 Day Avg. Volume22,645
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.28
Price to Sales (P/S)0.29
P/FCF Ratio-4.51
Enterprise Value/Market Cap-1.76
Enterprise Value/Revenue-0.59
Enterprise Value/Gross Profit-0.78
Enterprise Value/Ebitda12.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high gross margins (~68–78%) indicate durable pricing power and asset-light assay economics. These margins give the company room to invest in R&D and absorb SG&A while moving toward profitability, supporting long-term margin sustainability even if revenue growth is uneven.
Conservative Balance SheetVery low leverage and a multi-hundred-million RMB cash position materially reduce refinancing risk and provide operational runway. This balance-sheet strength supports continued investment in assays and regulatory work without immediate financing pressure, improving resilience over months.
Regulatory & Product AdvancesPatents, positive MRD data, and priority-review status are structural competitive assets: they protect IP, improve clinical credibility, and can unlock higher-value CDx and hospital adoption. These milestones can drive durable demand and deepen biotech partnerships over the medium term.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow means the business still consumes capital to run and grow. Even with improved burn, ongoing cash deficits raise the likelihood of future fundraising, which can dilute equity or constrain strategic flexibility over the next several quarters.
Weak Revenue TrendStagnant-to-declining revenue limits operating leverage and the company’s ability to convert strong gross margins into net profits. A sharp 2025 decline versus 2024 suggests demand or execution headwinds that could slow path to sustained profitability absent recurring top-line growth.
Revenue Mix VolatilityGreater reliance on in-hospital and pharma R&D revenue increases lumpiness and execution risk, as biopharma project timing and hospital adoption can be irregular. This makes short-to-medium-term revenue visibility weaker and complicates capacity planning and margin predictability.
Burning Rock Biotech News
BNR FAQ
What was Burning Rock Biotech Ltd.’s price range in the past 12 months?
Burning Rock Biotech Ltd. lowest stock price was $2.49 and its highest was $41.72 in the past 12 months.
What is Burning Rock Biotech Ltd.’s market cap?
Burning Rock Biotech Ltd.’s market cap is $179.23M.
When is Burning Rock Biotech Ltd.’s upcoming earnings report date?
Burning Rock Biotech Ltd.’s upcoming earnings report date is Jun 02, 2026 which is in 15 days.
How were Burning Rock Biotech Ltd.’s earnings last quarter?
Burning Rock Biotech Ltd. released its earnings results on Mar 12, 2026. The company reported -$0.206 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.206.
Is Burning Rock Biotech Ltd. overvalued?
According to Wall Street analysts Burning Rock Biotech Ltd.’s price is currently Overvalued.
Does Burning Rock Biotech Ltd. pay dividends?
Burning Rock Biotech Ltd. does not currently pay dividends.
What is Burning Rock Biotech Ltd.’s EPS estimate?
Burning Rock Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Burning Rock Biotech Ltd. have?
Burning Rock Biotech Ltd. has 8,813,858 shares outstanding.
What happened to Burning Rock Biotech Ltd.’s price movement after its last earnings report?
Burning Rock Biotech Ltd. reported an EPS of -$0.206 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.6%.
Which hedge fund is a major shareholder of Burning Rock Biotech Ltd.?
Currently, no hedge funds are holding shares in BNR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Burning Rock Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.28%
12-Months-Change
Fundamentals
Return on Equity
-9.93%
Trailing 12-Months
Asset Growth
-3.21%
Trailing 12-Months
Company Description
Burning Rock Biotech Ltd.
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.